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Eleven studies now report significant associations between schizophrenia and certain haplotypes of single-
nucleotide polymorphisms in the gene encoding dysbindin-1 at 6p22.3. Dysbindin-1 is best known as dystro-
brevin-binding protein 1 (DTNBP1) and may thus be associated with the dystrophin glycoprotein complex 
found at certain postsynaptic sites in the brain. Contrary to expectations, however, we found that when 
compared to matched, nonpsychiatric controls, 73–93% of cases in two schizophrenia populations displayed 
presynaptic dysbindin-1 reductions averaging 18–42% (P = 0.027–0.0001) at hippocampal formation sites 
lacking neuronal dystrobrevin (i.e., β-dystrobrevin). The reductions, which were not observed in the anterior 
cingulate of the same schizophrenia cases, occurred specifically in terminal fields of intrinsic, glutamatergic 
afferents of the subiculum, the hippocampus proper, and especially the inner molecular layer of the dentate 
gyrus (DGiml). An inversely correlated increase in vesicular glutamate transporter-1 (VGluT-1) occurred in 
DGiml of the same schizophrenia cases. Those changes occurred without evidence of axon terminal loss or 
neuroleptic effects on dysbindin-1 or VGluT-1. Our findings indicate that presynaptic dysbindin-1 reduc-
tions independent of the dystrophin glycoprotein complex are frequent in schizophrenia and are related to 
glutamatergic alterations in intrinsic hippocampal formation connections. Such changes may contribute to 
the cognitive deficits common in schizophrenia.
Introduction
Genetic susceptibility plays an important role in the pathogenesis 
of schizophrenia, the heritability of which is now estimated to be 
82–84% (1). Since schizophrenia is a severe mental disorder with a 
lifetime prevalence of 0.55% worldwide (2), the search for genetic 
susceptibility loci has been intensive (3–7). In 2002, significant asso-
ciations were reported for the first time between schizophrenia and 
haplotypes of single-nucleotide polymorphisms (SNPs) in specific 
genes (6–9). Among those were sets of SNPs in the gene encoding 
dysbindin-1, situated at chromosome locus 6p22.3 (10). Other 
known forms of dysbindin (dysbindin-2 and dysbindin-3) are not 
encoded at known schizophrenia-susceptibility loci (M. Benson and 
D. Blake, unpublished observations).
A significant association between schizophrenia and various dys-
bindin-1 haplotypes has now been reported in populations from 
England (11), Ireland (10, 12, 13), Wales (13), The Netherlands (14), 
Germany/Hungary/Israel (15), Sweden (16), Bulgaria (17), China, 
(18, 19), and Japan (20). Only two studies have failed to replicate 
such findings. One analyzed an Irish population (21) in which sub-
sequent analysis showed that a haplotype containing an SNP in 
the dysbindin-1 promoter region actually was more common in 
patients with schizophrenia than in control subjects (6, 13). The 
remaining negative study, of German and Polish populations (16), 
did not test haplotypes that included the promoter SNP.
The dysbindin-1 gene is thus among the most promising sus-
ceptibility genes for schizophrenia (6, 7, 22). While two prelimi-
nary studies on prefrontal brain homogenates report decreased 
dysbindin gene (23) and protein expression (24) in schizophre-
nia, it remains unclear how such alterations may contribute to 
the cognitive and behavioral features of the disorder. Our limited 
knowledge of the protein is nevertheless sufficient to suggest 
hypotheses testable with immunohistochemistry. Dysbindin-1 is 
a 40- to 50-kDa protein expressed neuronally (25) in many areas 
of the human brain (10). It is best known as a dystrobrevin-bind-
ing protein 1, DTNBP1, capable of binding both α- and β-dystro-
brevins (25, 26). Dystrobrevins are components of the dystrophin 
glycoprotein complex (27), which is concentrated at postsynaptic 
densities in diverse brain areas (28, 29). Both α- and β-dystro-
brevin are found in the brain (29, 30), but only the β isoform is 
expressed in neurons, where it is associated primarily with post-
synaptic densities (29).
Dysbindin-1’s ability to bind β-dystrobrevin and thus interact 
with the dystrophin glycoprotein complex at synaptic sites implies 
that dysbindin-1 polymorphisms may enhance susceptibility to 
schizophrenia by altering synaptic mechanisms. Such alterations 
are among the few neurobiological hallmarks of schizophrenia 
(31, 32). Given evidence of relatively high allelic variation in regu-
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latory sequences of the dysbindin-1 gene in the human brain (33), 
we tested the hypothesis that dysbindin-1 protein levels are altered 
at synaptic sites in multiple brain areas of individuals with schizo-
phrenia. Priority was given to immunohistochemical tests, because 
they allow anatomical localization of any synaptic protein changes 
within specific neural systems. This is the level of brain organiza-
tion at which genetic variations can affect cognition and behavior 
(34). We focus here on the hippocampal formation (HF), because 
it displays an unusual combination of features important to the 
present study: postsynaptic densities linked to the dystrophin 
glycoprotein complex (35, 36), frequent synaptic abnormalities in 
schizophrenia (37, 38), and an important role in mediating cogni-
tive and behavioral aspects of the disorder (39).
Methods
Research design and subjects studied. A matched-pairs design was used 
to compare postmortem tissue from 17 nonpsychiatric controls 
and 17 patients with schizophrenia who had participated in a 
longitudinal study of prospectively diagnosed subjects that was 
approved by an Institutional Review Board at the University of 
Pennsylvania and conducted by the Schizophrenia Research Cen-
ter at that university (40). Autopsy consent was obtained from a 
family member or legal guardian in all cases. Psychiatric subjects 
met DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 
fourth edition; American Psychiatric Association, Washington, 
DC, USA) diagnostic criteria for schizophrenia as determined in 
consensus conference after review of medical records, direct clini-
cal assessments of patients, and interviews with caregivers. Con-
trol and psychiatric subjects were matched for sex, age (within 5 
years), postmortem interval (PMI; within 7 hours), fixative used 
(ethanol, formalin, or Bouin’s fixative), and cerebral hemisphere 
studied (left or right). Neuropathological examination revealed no 
degenerative processes in control or psychiatric cases (i.e., there 
was no evidence of gross cell loss, infarcts, or abnormal densities of 
amyloid plaques, neurofibrillary tangles, or Lewy bodies).
A second sample of 15 nonpsychiatric and 15 schizophrenia cases 
in the Stanley Foundation’s standardized collection of formalin-
fixed brains (41) was studied. They were matched for sex and age 
(within 10 years); there were no significant group differences 
between control and schizophrenia cases in PMI or hemisphere 
studied. Demographic data on the University of Pennsylvania and 
Stanley Foundation cases are summarized in Table 1. Tissues from 
15 bipolar and 15 major-depressive cases from the Stanley Foun-
dation were also studied.
Tissue preparation. Coronal brain slabs containing intermediate 
rostrocaudal levels of the HF and several other brain regions (e.g., 
anterior cingulate cortex, superior temporal cortex, striatum, and 
cerebellum) were removed at autopsy. Tissue from one hemisphere 
was fresh-frozen at –80°C for Western blotting and in situ hybrid-
ization. Tissue from the other hemisphere was fixed in neutral-
buffered formalin (10%), ethanol (70% in saline), or Bouin’s fixa-
tive for 24–48 hours and embedded in paraffin. Fixed tissue from 
the University of Pennsylvania sample was cut coronally at 6 μm 
on a rotary microtome tested to assure invariant section thickness, 
and mounted on 3-aminopropyltriethoxysilane–coated slides (42). 
Tissue from the Stanley Foundation sample was cut coronally at 
10 μm in the case of formalin-fixed, paraffin-embedded blocks for 
immunohistochemistry, or 14 μm in the case of fresh-frozen mate-
rial for in situ hybridization.
In situ hybridization. Dysbindin-1 gene expression was studied 
in six normal Stanley Foundation cases (mean age 49.7 years) by 
in situ hybridization on sections through the HF and adjoining 
cortical areas.
Radiolabeled sense and antisense riboprobes were synthesized 
using a cDNA for human dysbindin-1 as template. The cDNA 
(AI337229; American Type Culture Collection, Manassas, Vir-
ginia, USA; catalog no. 3064549) encompassed 531 C-terminal 
nucleotides of a 1,300-nucleotide transcript of human dysbindin. 
It was inserted into pT7T3pac vectors. The plasmids were linear-
ized by digestion with HindIII for synthesis of sense probes or XhoI 
for antisense probes. Riboprobes were then synthesized using T7 
(for sense probes) or T3 (for antisense) RNA polymerase in the 
presence of α35S-CTP and α35S-UTP (Amersham Biosciences, 
Piscataway, New Jersey, USA). The sense and antisense probes were 
size-fractionated on a sequencing gel. Those probes yielding dis-
tinct bands were used for hybridization.
Frozen tissue sections were prepared for in situ hybridization by 
immersion in 4% paraformaldehyde (pH 7.4) for 10 minutes and 
then rinsed sequentially in 0.1 M triethylethanolamine (TEA), 0.1 
M TEA plus 0.25% acetic anhydride, and 2× saline sodium citrate 
(SSC, pH 7.0). Probes labeled with α35S-CTP and α35S-UTP were 
added to the slides (9.0 × 105 cpm per slide) in 90 μl of hybridiza-
tion buffer (50% formamide, 300 mM NaCl, 20 mM Tris [pH 8.0], 5 
mM EDTA, 1× Denhardt’s solution, 10% dextran sulfate [50% wt/
vol], 10 mM DTT [dithiothreitol]). Slides were then covered with 
Parafilm (Fisher Scientific, Pittsburgh, Pennsylvania, USA) and 
incubated for 18 hours at 55°C, after which they were washed in 
2× SSC for 15 minutes twice. The sections were next treated with 
RNase A solution (20 mg/ml in 500 mM NaCl and 10 mM Tris) for 
30 minutes at 37°C. A serial stringency washing was performed by 
rinsing in 2× SSC at room temperature for 10 minutes twice and 
then in 0.1× SSC at 65°C for 2 hours. Air-dried slides were exposed 
to emulsion (NTB-2; Eastman Kodak, Rochester, New York, USA) 
for 9 days, developed in D19 (Eastman Kodak), stabilized in fixative 
Eastman Kodak), and counterstained lightly with cresyl violet. Only 
background labeling was seen with the sense probe (Figure 1F).
Table 1
Case demographics
 University of Pennsylvania cases Stanley Foundation cases
Parameters Control (n = 17) Schizophrenia (n = 17) Control (n = 15) Schizophrenia (n = 15)
Mean age: yr (range) 79.3 (65–93) 78.4 (68–90) 48.1 (29–68) 44.2 (25–62)
Sex ratio: female/male 12/5 12/5 6/9 6/9
Mean PMI: h (range) 12.1 (3.5–26) 13.5 (7–24) 23.7 (8–42) 33.7 (12–61)
Hemisphere studied: left/right 10/7 10/7 7/8 6/9
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Antibodies and antibody specificity. Dysbindin-1 was detected with 
a rabbit polyclonal antibody (PA3111Ae2) raised against the C-
terminus of mouse dysbindin (amino acids 196–352). PA3111Ae2 
recognizes peptides of the same molecular weight as dysbindin 
isoforms in COS-7 cells only when they are transfected with a 
dysbindin-1 expression construct (Figure 2A). The antibody does 
not recognize other proteins expressed by COS-7 cells transfected 
with expressed sequence tags bearing significant similarity to 
the dysbindin-1 gene (e.g., dysbindin-2; Figure 2B). PA3111Ae2’s 
ability to recognize antigen (Figures 3 and 4) was blocked by 
preadsorption with 10–7 M M10FL, a recombinant, full-length 
dysbindin-1 peptide (Figure 4, compare C and D). Omission of 
PA3111Ae2 (or any other antibody used in this study) resulted 
in immunohistochemical runs without visible reaction prod-
uct. Preliminary tests with a second dysbindin-1 antibody raised 
against the complete mouse protein (rabbit polyclonal antibody 
M10FLA) gave essentially the same pattern of immunoreactivity 
as PA3111Ae2 in mouse and human brain tissue.
β-Dystrobrevin was detected with a rabbit polyclonal antibody 
(β521) raised against a unique C-terminal region of the mouse 
antigen (30). A neuronal nucleus antibody (NeuN) (MAB377; 
Chemicon International Inc., Temecula, California, USA) was used 
to label neurons selectively. Presynaptic terminals were identified 
with mouse mAb’s against synaptophysin (M0776; DAKO Corp., 
Carpinteria, California, USA) and synapsin-1 (106 001; Synaptic 
Systems GmbH, Göttingen, Germany). Glutamatergic terminals 
common in the HF (43) were visualized selectively with a guinea 
pig polyclonal antibody to vesicular glutamate transporter-1 
(VGluT-1) (AB5905; Chemicon International Inc.).
Western blotting. Fresh-frozen brain tissue was used from four 
normal human cases with low PMIs (3.5–7 hours) in the Univer-
sity of Pennsylvania brain bank. Western blotting was performed 
as described previously (25, 30) using dysbindin-1 antibody 
PA3111Ae2 (1:100). Blots were incubated at 4°C overnight in the 
primary antibody, washed thoroughly, and incubated for 1 hour at 
room temperature with an HRP-conjugated anti-rabbit secondary 
antibody (Jackson ImmunoResearch Laboratories Inc., West Grove, 
Pennsylvania, USA). They were developed with a chemiluminescence 
detection kit (Pierce Biotechnology Inc., Rockford, Illinois, USA).
Immunohistochemistry. Dewaxed sections were immersed in 5% 
hydrogen peroxide dissolved in absolute methanol for 30 min-
utes to quench endogenous peroxidase activity. If antigen retrieval 
was desirable, as was the case for dysbindin-1, β-dystrobrevin, and 
NeuN, the sections were then boiled in 1 mM EDTA in 0.1 M Tris 
buffer (pH 8.0) for 10 minutes (44). After cooling for 20 minutes 
and rinsing in water, sections later given silver intensification 
(dysbindin-1, β-dystrobrevin, and synapsin-1) were soaked in 0.5% 
sodium borohydride for 5 minutes. Following two changes of Tris-
Triton (0.01% Triton X-100 in 0.1 M Tris-HCl buffer, pH 7.6), sec-
tions processed for all antigens were blocked for 45 minutes in 2% 
horse serum dissolved in Tris-Triton and were then incubated in 
the primary antibody overnight (14–18 hours) at 4°C. Following 
Tris-Triton rinses, sections were incubated in a biotinylated sec-
ondary antibody (Vector Laboratories Inc., Burlingame, California, 
USA) for an hour at room temperature, treated for another hour at 
room temperature with an avidin-biotin-peroxidase complex made 
Figure 1
Dysbindin gene expression in normal human HF, demonstrated by in 
situ hybridization. The tissue was counterstained for Nissl substance. 
All principal neurons in the DG and CA1–3 were labeled with the anti-
sense riboprobe, as seen at low magnification (A). Gene expression in 
CA1 (B) and in the DGg (E) is lower than in CA3 (C) or in the DGh (D). 
Comparison of DGg with antisense (E) and with sense riboprobes (F) 
shows that the latter produced very little cell labeling. Scale bar in A: 1 
mm; scale bars in B–F: 20 μm.
Figure 2
Tests of dysbindin-1 antibody specificity in COS-7 cells. Such cells nor-
mally express no detectable dysbindin. (A) The antibody PA3111Ae2 
(1:100) recognizes dysbindin-1 only in COS-7 cells transfected with dys-
bindin-1 expression constructs. It does not recognize antigens in COS-7 
cells transfected with dysbindin-2 expression constructs. (B) The antibody 
M10RP-FLA (1:50) recognizes dysbindin-2, which is of lower molecular 
weight than dysbindin-1. (C) Equal loading of samples was demonstrated 
with β-tubulin antibody T4026 from Sigma-Aldrich (1:5,000).
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from a Vectastain Elite ABC kit (Vector Laboratories Inc.), and 
developed for 10 minutes in a solution containing 0.05% diami-
nobenzidine (DAB, HK 124-7K; BioGenex, San Ramon, Califor-
nia, USA ) and 0.03% hydrogen peroxide (HK 126-7K, BioGenex) 
in Tris-Triton. For NeuN (1:100), synaptophysin (1:1,000), and 
VGluT-1 (1:5,000–1:10,000), the DAB solution was supplemented 
with 0.25% NiSO4.6H2O to amplify the immunohistochemical sig-
nal. For dysbindin-1 (1:300), β-dystrobrevin (1:100), and synapsin-1 
(1:500), no NiSO4 was added to the DAB solution. Signal ampli-
fication for those antigens was maximized instead by on-the-slide 
silver intensification at 60°C for 90 minutes using the method 
of Teclemariam-Mesbah et al. (45). After clearing in xylenes, tis-
sue sections were coverslipped under Cytoseal 60 (Richard-Allan 
Scientific, Kalamazoo, Michigan, USA). Dysbindin-1 (1:400) and 
VGluT-1 (1:5,000) were colocalized with immunofluorescence 
using Alexa 594 and 488 secondary antibodies (Molecular Probes 
Inc., Eugene, Oregon, USA), respectively.
Mouse controls. Male C3H mice (n = 16) (Charles River Labora-
tories Inc., Wilmington, Massachusetts, USA) were used in accor-
dance with NIH guidelines on animal care. Under anesthesia (100 
mg/kg ketamine and 10 mg/kg xylazine intraperitoneally), pel-
lets of Medisorb bioabsorbable polymer (Alkermes Inc., Cincin-
nati, Ohio, USA) were implanted subcutaneously (46). The pellets 
contained polymer alone in eight of the mice and polymer plus 
haloperidol (H1512; Sigma-Aldrich, St. Louis, Missouri, USA) in 
eight other mice. The drug-laden pellets release approximately 
2 mg/kg of haloperidol (Haldol) per day. Ten weeks after pellet 
implantation, the animals were killed according to a protocol 
approved by an Institutional Animal Care and Use Committee 
at the University of Pennsylvania. Their brains were extracted, 
immersed overnight in neutral-buffered formalin or 70% ethanol 
in saline, and then embedded in paraffin blocks for sectioning 
at 6 μm. Sections through the HF were reacted for dysbindin-1, 
β-dystrobrevin, synapsin-1, synaptophysin, or VGluT-1 as described 
above for human material. A correction factor for fixation effects 
on immunoreactivity was used to compare results from mice fixed 
in formalin versus ethanol.
Image analysis. Immunoreactivity was quantified by net OD, 
defined as the OD of a region of interest minus the OD of the 
background (i.e., neighboring white matter). OD analysis was per-
formed on high-resolution, gray-scale photomontages made on a 
motorized microscope stage with Image-Pro Plus software (Media 
Cybernetics Inc., Silver Springs, Maryland, USA). Quantitative 
comparisons of antigens in controls and psychiatric cases were per-
formed only on sections reacted in the same immunohistochemical 
run and photographed at the same verified light intensity. In addi-
tion to OD, Image-Pro Plus was used to quantify neuronal cell 
areas, neuronal densities, neuropil areas, neuropil densities, and 
mean laminar thickness. Operators were blind to any identifying 
information throughout data accrual and analysis.
Statistics. Statistical significance of differences across matched pairs 
was assessed with the Wilcoxon matched-pairs signed-ranks test. Cor-
relations are given as Spearman r correlation coefficients. P values less 
than 0.05 were defined as statistically significant.
Figure 3
Dysbindin-1 isoforms in human brain regions. PA3111Ae2 (1:100) 
recognizes two dysbindin-1 isoforms, as shown in a Western blot on 
two cases here. Lanes were loaded with equal amounts of protein. 
The cerebellar cortex lacks detectable amounts of isoform 1b in both 
cases. STC, superior temporal cortex; CC, cerebellar cortex.
Figure 4
Dysbindin-1 immunohistochemistry of the human HF. (A) Diagram of 
the HF, showing subdivisions and layers. The DGiml is highlighted in red 
to indicate a major neuropil locus of dysbindin-1. The subjacent granule 
cell layer is shown in green. (B) Dysbindin-1 immunoreactivity (ir) with 
PA3111Ae2 (1:300) in the section diagrammed in A. (C and D) Antibody 
specificity test showing that dysbindin-1 immunoreactivity (C) can be 
eliminated by preadsorption of PA3111Ae2 with 10–7 M recombinant dys-
bindin-1, M10FL (D). (E and F) Dysbindin-1–positive neurons in CA3 (E) 
and the DGh (F). (G and H) Dysbindin-1 in the DG. The higher-magnifi-
cation view in H shows dendrites of hilar neurons containing dysbindin 
penetrating the granule cell layer (yellow arrowheads) and extending 
into the molecular layer (green arrowheads). Note the dense band of 
presynaptic dysbindin-1 in DGiml. CA3p, stratum pyramidal of CA3; PrS, 
presubiculum; S, subiculum. Hippocampal layers: l, stratum lucidum; m, 
stratum moleculare; o, stratum oriens; p, stratum pyramidal; r, stratum 
radiatum. Components of the DG: g, granule cell layer; h, hilus; iml, 
inner molecular layer; oml, outer molecular layer. Scale bars in A and B: 
2 mm; in C and D: 200 μm; in E–H: 50 μm.
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Results
As defined by Scharfman et al. (47), the HF consists of three struc-
tures: (a) the hippocampus proper (i.e., cornu ammonis fields 1–3 
[CA1–3]); (b) the dentate gyrus (DG); and (c) the subiculum. Their 
relative locations are indicated in Figures 1A and 4A. Each com-
ponent of the HF contains a compact neuronal layer (Figure 1A) 
consisting of small granule cells in the DG and large pyramidal 
cells in the hippocampus and subiculum (48, 49). Dendrites of 
the compact cell layer extend into cell-poor, synapse-rich layers 
(e.g., strata oriens and radiatum in the hippocampus and stratum 
moleculare in the DG; Figure 4A).
Normal dysbindin-1 gene expression. In situ hybridization with an 
antisense riboprobe (Figure 1) revealed prominent dysbindin-1 
gene expression in all principal neuronal populations of the HF, 
namely pyramidal neurons in the subiculum and CA1–3, granule 
cells in the dense cell layer of the DG (DGg), and polymorph cells 
in the hilus of the DG (DGh). All neurons in those populations 
expressed dysbindin-1 mRNA, but the expression levels varied 
from low to moderate in CA1 and DGg and high to maximal in 
CA2, CA3, and DGh (Figure 1, B–E). Variable gene expression 
also occurred in neurons of neighboring cerebrocortical areas 
(entorhinal and inferior temporal cortex), though usually at 
distinctly lower levels than in CA2, CA3, or DGh. There was no 
evidence of dysbindin-1 gene expression in cells of glial size or in 
areas rich in glia, such as white matter. No clear cell labeling was 
observed in the HF or neighboring cerebral cortex with a sense 
riboprobe (e.g., Figure 1F).
Normal dysbindin-1 isoforms. Western blots demonstrated the 
presence of dysbindin-1 protein in the HF, as well as in the supe-
rior temporal cortex and cerebellar cortex (Figure 3). Two dysbin-
din-1 isoforms, 1a and 1b, were detected with molecular masses 
of about 50 and 40 kDa, respectively. The HF and cerebral cor-
tex contained both isoforms, but the cerebellar cortex lacked the 
lower–molecular weight isoform (1b), which is a splice variant of 
full-length dysbindin-1a (25).
Normal dysbindin-1 distribution. Dysbindin-1 immunohistochemistry 
(Figure 4) was successfully enhanced by heat-induced epitope 
retrieval (44) and fine-grain silver intensification (45). The distri-
bution of dysbindin-1 protein matched that of dysbindin-1 gene 
expression. Immunoreactivity was accordingly limited to neu-
rons, was strong in pyramidal cells of CA2 and CA3, and was espe-
cially strong in DGh polymorph cells. Neurons in DGg, CA1, the 
subiculum, and surrounding cortical areas were less immunoreac-
tive (Figure 4, B and E–H). Nevertheless, all principal HF neurons 
Figure 5
Colocalization of dysbindin-1 labeled with Alexa 594 (red) and VGluT-1 labeled with Alexa 488 (green) in human DG. The single-channel images 
in A and B are merged in C, which shows that dysbindin-1 and VGluT-1 are coextensive in DGiml. In DGg, only dysbindin-1 is present. In DGh, 
dysbindin-1 is present in many neurons (not seen clearly here), while VGluT-1 alone is present in mossy fiber terminals of granule cell axons. 
For abbreviations, see Figure 4. Scale bars: 100 μm.
Figure 6
Comparison of control (Ctrl) and schizophrenia 
(Sz) cases for β-dystrobrevin (A–D), dysbin-
din-1 (E–H), and VGluT-1 (I–L) in the HF. The 
blue-gray color of the VGluT-1 panels reflects 
NiSO4 intensification of immunohistochemical 
reaction product. Lower-magnification views 
indicate extent of HF changes in schizophrenia. 
Note widespread reductions in dysbindin-1 in 
F. Higher-magnification views of boxed areas 
of the DG in A, B, E, F, I, and J are shown in 
C, D, G, H, K, and L, respectively. Note the 
absence of β-dystrobrevin in DGiml. Arrows 
indicate DGiml changes in schizophrenia: 
a loss of dysbindin-1 (H) and an increase in 
VGluT-1 (L). For abbreviations, see Figure 4. 
Scale bars in low-magnification panels: 1 mm; 
in high-magnification panels: 50 μm.
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and their cell nuclei contained dysbindin-1 (Figure 4, E and F). The 
antigen generally extended far into dendrites only in the strongly 
immunoreactive neurons of CA2, CA3, and DGh (Figure 4, E and F). 
Immunoreactivity was occasionally seen there in primary dendritic 
branches, but never in dendritic spines (Figure 4, E and F).
Dysbindin-1 was not limited to neuronal cell bodies and den-
drites, however. The HF was distinguished from most other 
brain areas examined by bands of diffuse, granular dysbindin 
immunoreactivity not attributable to somatic, dendritic, or glial 
labeling. As shown in Figure 4, such immunoreactivity filled three 
cell-poor, synapse-rich areas: (a) strata oriens and radiatum of 
CA1–3, (b) the neuropil among pyramidal cells of CA1, and (c) the 
inner molecular layer of the dentate gyrus (DGiml). Those areas 
were also filled with diffuse, granular VGluT-1 immunoreactivity 
(Figures 5B and 6, I and J). Dysbindin-1 thus appeared to be locat-
ed in axon terminals of glutamatergic pathways arising within (i.e., 
intrinsic to) the HF (see 49). The protein was not 
localized in known terminal fields of nonglutama-
tergic transmitter systems in the HF (i.e., choliner-
gic, GABAergic, or monoaminergic systems).
Special attention was given to the polymorph 
neurons in the dentate hilus (Figure 4F). They 
were richer in dysbindin-1 than any other cells we 
observed in our survey of the human and the mouse 
brain. Their density was not significantly different 
from that of NeuN-labeled neurons in DGh (Table 
2), indicating that all DGh neurons contain dysbin-
din-1. Some hilar neurons gave rise to long dysbin-
din-containing dendrites extending into the inner 
and outer molecular layers of the DG (Figure 4, 
G and H). The inner molecular layer (DGiml) was 
marked by an unusually dense band of diffuse, gran-
ular dysbindin-1 likely to be presynaptic as noted 
above (Figure 4, B, C, G, and H). Colocalization tests 
showed that the band was coextensive with the glu-
tamate terminal marker VGluT-1 (Figure 5). Those 
tests also demonstrated that many dysbindin-1 cell 
bodies in the dentate hilus were encased by VGluT-1 
immunoreactivity, presumably in glutamatergic 
mossy fiber terminals of dentate granule cells.
Normal β-dystrobrevin distribution. The HF dis-
tributions of dysbindin-1 and β-dystrobrevin 
immunoreactivity were discordant. Although both 
antigens were found in neurons (granule, poly-
morph, and pyramidal cells; Figure 6, A–H), there 
was no overlap elsewhere. Of the two antigens, only 
dysbindin-1 was found in presynaptic fields of the 
HF (Figure 6; compare A with E and C with G).
Dysbindin-1 in schizophrenia cases. In terminal fields 
of intrinsic glutamatergic connections of the HF, 
dysbindin-1 reductions were common in schizophrenia cases com-
pared with their matched controls. A high percentage of the cases 
showed such reductions: 75% in the subiculum, 80% in CA1, 86% in 
CA2/3 stratum oriens, 93% in CA2/3 stratum radiatum, and 88% 
in DGiml (Figures 7 and 8). The mean neuropil reduction in dys-
bindin-1 immunoreactivity was 18% in the subiculum (Wilcoxon 
W = 37.0, P = 0.026), 21% in CA1 (W = 38.0, P = 0.027), 30% in CA2/3 
stratum oriens (W = 49.0, P = 0.003), 37% in CA2/3 stratum radia-
tum (W = 51.5, P = 0.0001), and 42% in DGiml (W = 71.5, P = 0.0003) 
(Figures 7 and 8). The neuropil reductions in the subiculum and 
CA1–3 were not accompanied by significant reductions of dysbin-
din-1 in the pyramidal cells giving rise to intrinsic, glutamatergic 
pathways in those HF areas. The parent cells of intrinsic, glutama-
tergic input to DGiml, however, showed reduced dysbindin-1 in 
65% of the schizophrenia cases compared with matched controls. 
The mean loss was 14% (W = 45.5, P = 0.03), which was significantly 
Table 2
Morphometric comparisons in DG (mean ± SD)
Feature Control cases (n = 17) Schizophrenia cases (n = 17) Significance of difference
Hilus neuron density (cells/mm2) 209.68 ± 78.31 237.28 ± 75.41 P = 0.30
Hilus dysbindin-1 neuron cell size (μm2) 163.57 ± 26.45 164.30 ± 29.50 P = 0.94
DGiml depth (μm in VGluT-1 preparations) 70.47 ± 23.07 62.27 ± 19.55 P = 0.30
  
Figure 7
Quantification of dysbindin-1 reductions in extrasomatic (i.e., neuropil) areas of the 
subiculum and hippocampus proper in schizophrenia compared to matched control 
cases in the University of Pennsylvania cohort. Data were collected only from neuropil 
known to contain terminals of glutamatergic pathways arising in the hippocampus. 
CA2/3 (o) and CA2/3 (r) respectively designate stratum oriens and stratum radiatum 
of CA2 and CA3. Relative OD was used to quantify dysbindin-1 immunoreactivity. 
Each data point in these bivariate graphs give the OD of dysbindin-1 immunoreactivity 
in a schizophrenia case (y axis) versus that in its matched control (x axis). Note 
that 73–93% of the data points lie below the diagonal lines, indicating that neuropil 
dysbindin-1 in all four brain areas was lower in the vast majority of the schizophrenia 
cases compared to matched controls.
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correlated with the mean 42% loss of dysbindin-1 in DGiml of the 
same cases (Spearman r = 0.43, P = 0.01).
Loss of dysbindin-1 in DGiml was replicated in younger, non-
institutionalized schizophrenia cases from the Stanley Founda-
tion (41). As in the University of Pennsylvania cohort, a high per-
centage of the cases (73%) exhibited reduced dysbindin-1 in DGiml 
compared with matched controls. The mean reduction was 24.9% 
(W = 37.0, P = 0.035; Figure 8B). Mean reductions of about 18% 
were found in DGiml of bipolar and depressive cases from the 
Stanley Foundation, but they were not significant (W = 20.0, 
P = 0.28 for bipolar cases; W = 31.0, P = 0.08 for depressive cases).
Dysbindin-1 immunoreactivity was nevertheless unaltered in 
another brain area affected in schizophrenia, specifically the anterior 
cingulate cortex (31). Analysis of 13 matched pairs from the Univer-
sity of Pennsylvania cohort used for HF analyses revealed no signifi-
cant changes in cell body or neuropil dysbindin-1 immunoreactivity 
within superficial or deep layers of the anterior cingulate cortex in 
schizophrenia (W = 3.5–13.5, P = 0.34–0.84). The disorder is thus not 
characterized by dysbindin-1 abnormalities in all brain areas.
VGluT-1 in schizophrenia cases. As noted above, dysbindin-1 and 
VGluT-1 are coextensive in DGiml (Figure 5). Since that raises the 
possibility that the two proteins are colocalized at presynaptic sites, 
we also measured VGluT-1 immunoreactivity in DGiml. While 
dysbindin-1 was decreased, VGluT-1 was elevated in 75% of the 
schizophrenia cases compared with their matched controls in the 
University of Pennsylvania cohort (Figures 6, I–L, and 8). The mean 
VGluT-1 elevation was 84% (W = 47.0, P = 0.01; Figure 8C). A signif-
icant inverse correlation was found between immunoreactivity for 
the two proteins in DGiml (Spearman r = –0.61, P = 0.0002; Figure 
8D). Elsewhere in the HF (CA1–3), no significant differences were 
found in VGluT-1 immunoreactivity between schizophrenia cases 
and their matched controls.
β-dystrobrevin in schizophrenia cases. No significant changes in β-dys-
trobrevin immunoreactivity were found in the HF of schizophrenia 
cases compared with matched controls (e.g., Figure 6, A–D).
Analysis of confounding variables. Our matched-pairs design con-
trolled for age, sex, PMI, type of fixative used, and cerebral hemi-
sphere studied. Neither dysbindin-1 nor VGluT-1 OD was sig-
nificantly correlated with subject age, sex, PMI, or antipsychotic 
exposure measured in equivalent chlorpromazine doses taken 
daily one month prior to death. Nor did chronic haloperidol treat-
ment of mice significantly affect immunoreactivity for dysbindin-1 
(control vs. drug-treated animals [mean ± SD]: 966.51 ± 99.52 vs. 
1,054.98 ± 145.65, t = –1.42, P = 0.18) or VGluT-1 (2,016.13 ± 448.65 
vs. 2,073.65 ± 159.11, t = 1.35, P = 0.20) in DGiml. The pooled 
serum level of haloperidol in the drug-treated animals was 3.1 
ng/ml, which is a therapeutic level in humans (50). As detailed in 
Methods, neither the normal nor the schizophrenia cases exhib-
ited neuropathology. Moreover, the schizophrenia cases showed 
no loss or shrinkage of DGh neurons (Table 2; consistent with ref. 
49), no loss of DGiml thickness (Table 2), and no loss of the synap-
tic markers synaptophysin or synapsin-1 in DGiml (Figure 9).
Discussion
We found dysbindin-1 reductions in terminal fields of intrinsic 
glutamatergic connections in an unusually high percentage of two 
schizophrenia populations (73–93% depending on case popula-
tion and HF area). The average reduction ranged from 18% in the 
subiculum to 42% in DGiml and was significant in both popu-
lations studied. No such reductions were observed in bipolar or 
major-depressive cases, although there was a trend in that direc-
tion in the latter cases. Our research design excluded the possibility 
that the reductions were due to age, sex, neurodegeneration, PMI, 
fixation, or cerebral hemisphere studied. Neuroleptic medication 
could also be excluded as a contributing factor. Dysbindin-1 levels 
in our schizophrenia cases were not correlated with antipsychotic 
dosage a month before death. Nor did chronic haloperidol treat-
ment of mice affect dysbindin-1 levels in the HF, consistent with 
the recent finding that haloperidol has no effect on dysbindin-1 lev-
els in the rat brain (22). These considerations suggest that schizo-
phrenia itself is associated with the observed presynaptic dysbin-
din-1 reductions in the HF.
Possible cause(s) of dysbindin-1 reductions. Reductions in dysbindin-1 
gene and protein expression are reported in homogenates of the 
Figure 8
Quantification and correlation of dysbindin-1 and 
VGluT-1 in DGiml of schizophrenia and matched con-
trol cases. (A and B) Bivariate graphs (see Figure 7) 
showing that schizophrenia cases often display lower 
dysbindin-1 immunoreactivity in DGiml than matched 
controls in both the University of Pennsylvania and 
the Stanley Foundation cohorts. (C) Bivariate graph 
showing that schizophrenia cases often display high-
er VGluT-1 immunoreactivity in DGiml than matched 
controls in the University of Pennsylvania cohort. (D) 
Correlative levels of dysbindin and VGluT-1 in DGiml 
of the cases plotted in A and C.
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dorsolateral prefrontal cortex in schizophrenia (23, 24). Such 
changes may manifest early in life, given the finding that certain 
dysbindin-1 polymorphisms are associated with worse premorbid 
functioning in cases of childhood psychosis (52). It is possible, 
then, that altered dysbindin-1 expression early in life contributes 
to schizophrenia onset.
It seems doubtful, however, that dysbindin-1 haplotypes alone 
account for the protein reductions we observed in schizophrenia 
cases. The frequency of dysbindin-1 reductions that we observed 
in schizophrenia cases (73–93%) was far greater than the frequency 
of high-risk dysbindin-1 haplotypes (0–18%) reported in schizo-
phrenia populations (10, 12, 16). Other genetic and nongenetic 
factors would seem to be involved (e.g., genetic epistasis, altered 
transcriptional regulation, and/or abnormal protein metabolism). 
The unusual frequency of the presynaptic protein reductions 
we observed suggests, moreover, that dysbindin-1 binds 
unidentified synaptic proteins near the end of a final com-
mon pathway by which both genetic and nongenetic factors 
promote the pathogenesis of schizophrenia.
Synaptic dysbindin-1 and the dystrophin glycoprotein complex. 
An unexpected conclusion of the present study is that the 
dystrophin glycoprotein complex is unlikely to be associated 
with synaptic dysbindin-1 levels in schizophrenia. The synap-
tic dysbindin-1 reductions we found were presynaptic, where-
as the dystrophin glycoprotein complex in brain synapses is 
exclusively postsynaptic (28, 29). The central component of 
the complex, dystrophin, is found in neurons and dendrites 
of the human HF but is absent from presynaptic fields of that 
structure (see ref. 53). We found the same to be true for the 
dystrophin binding partner β-dystrobrevin, which was absent 
from presynaptic fields of the HF. Dysbindin-1 in the HF thus 
appears to play a presynaptic role independent of β-dystrobrevin 
and the dystrophin glycoprotein complex.
Figure 9
Synapsin-1 and synaptophysin levels in DGiml of schizophre-
nia matched control cases. No significant differences between 
schizophrenia and control cases were found in relative OD of 
either synapsin-1 (A) or synaptophysin (D) immunoreactivity 
in DGiml. Photomicrographs from sample matched pairs 
illustrate synapsin-1 (B and C) and synaptophysin (E and F) 
immunohistochemistry in control and schizophrenia cases. Black 
lines in E and F indicate the boundary between the inner and 
outer molecular layers of the DG, evident in neighboring sec-
tions reacted for VGluT-1. The blue-gray color in E and F reflects 
NiSO4 intensification of immunohistochemical reaction product. 
Scale bars: 100 μm.
Figure 10
Summary of results in the context of information flow in the HF. Dys-
bindin-1 in the HF (A) was found in neurons that supply intrinsic glu-
tamatergic connections in that structure. As diagrammed in B, dysbin-
din-1 neurons in DGh (red dots) innervate DGiml (red band); those in 
CA2 and CA3 (green dots) innervate much of CA1–3 (green field); and 
those in CA1 (yellow dots) innervate the subiculum (yellow field) and 
entorhinal cortex (ERC). Those intrinsic glutamatergic pathways are part 
of a broader series of HFl circuits diagrammed in C. The blue star-bursts 
there indicate the loci of dysbindin-1 reductions found in schizophrenia, 
which potentially disrupt normal glutamatergic transmission in the DG, 
hippocampus proper, and subiculum. See Discussion for consideration 
of the possible consequences for information flow in the HF. D, den-
drites; DGoml, outer molecular layer of the DG; G, dentate granule cell; 
H, dentate hilar cell; mf, mossy fiber; pp, perforant path; r/o, strata radia-
tum and oriens; sc, Schaffer collateral. Scale bars in A and B: 2 mm.
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Potential roles of dysbindin-1 in glutamatergic neurotransmission. The 
presynaptic function of dysbindin-1 may be related to VGluT-1, 
which is the only vesicular glutamate transporter present in much 
the HF (43). The inverse relationship we found between the two 
proteins in DGiml (i.e., a decrease in dysbindin-1 and an increase 
in VGluT-1; Figure 8D) suggests an effect of dysbindin-1 on 
VGluT-1 expression, synthesis, or degradation in that HF area. An 
effect on degradation is consistent with recent evidence that dys-
bindin-1 binds proteins (muted and pallidin) that promote assem-
bly of lysosome-related organelles (26). Presynaptic lysosomes 
are, in fact, common in the adult DGiml (54). Elevated VGluT-1 
in schizophrenia may thus result from reduced lysosomal activ-
ity and/or a compensatory response to known decrements in DG 
glutamate-receptor expression in the disorder (55–57). Such possi-
bilities deserve further study given mounting evidence for glutama-
tergic dysfunction in schizophrenia (58) and for an association of 
that disorder with several genes encoding proteins that affect glu-
tamatergic transmission (9, 59–61). An additional possibility is that 
presynaptic dysbindin-1 reductions can alter glutamatergic trans-
mission without affecting VGluT-1, the levels of which were unal-
tered in HF areas outside the DGiml in our schizophrenia cases. 
Anatomical loci of dysbindin-1 reductions. Dysbindin-1 gene and pro-
tein expression were high in the HF compared with surrounding 
cerebrocortical areas. Both types of expression were highest, however, 
in the principal neurons of CA2, CA3, and DGh. These cells are the 
source of intrinsic, glutamatergic connections in the HF (49). Such 
connections innervate certain cell-poor layers of the hippocampus 
(i.e., strata oriens and radiatum) and the DG (i.e., its inner molecu-
lar layer) (49). These are the same cell-poor layers we found filled 
with diffuse, granular dysbindin-1 and VGluT-1 immunoreactivity 
indicative of presynaptic localization. No other synaptic fields in the 
HF were immunoreactive for dysbindin-1 or VGluT-1.
It is consequently likely that dysbindin-1 neurons of CA2, CA3, 
and DGh are the source of presynaptic dysbindin-1 within intrin-
sic, glutamatergic terminals of the HF (Figure 10B). That is espe-
cially likely in the case of DGh cells, all of which were found to be 
intensely immunoreactive for dysbindin-1. DGh cells provide the 
only substantial input to DGiml (49), which is known to be gluta-
matergic (62–64). That would explain the significant correlation 
between the dysbindin-1 reduction in DGh cells and that in DGiml 
in our schizophrenia cases. We may thus interpret the unusually 
dense band of presynaptic dysbindin in DGiml as the terminal field 
of glutamatergic input from DGh, consistent with our finding that 
dysbindin-1 and VGluT-1 are coextensively distributed in DGiml.
Such observations lead to the conclusion that presynaptic dys-
bindin in the HF is localized in intrinsic, glutamatergic terminals 
of that structure. It is in those terminals, then, that reductions in 
presynaptic HF dysbindin are most likely to occur in schizophre-
nia. Since the glutamatergic terminals in the areas affected contain 
VGluT-1 and not VGluT-2 (43), the loss must occur specifically in 
terminals containing VGluT-1.
Potential consequences of the dysbindin reductions. If dysbindin-1 reduc-
tion impairs normal neurotransmission in the DG and CA3 (e.g., via 
an effect on VGluT-1), information flow through the HF would also 
be impaired. Figure 10C diagrams the primary course of the infor-
mation flow, much of which derives from entorhinal cortex input 
that conveys information from many cerebrocortical areas (48, 49, 
65). Via the perforant path, entorhinal input terminates in the outer 
molecular layer of the dentate gyrus on dendrites of granule (49) 
and hilar (66, 67) cells. As noted earlier, all DGh cells are rich in 
dysbindin-1 and thus necessarily include DGh cells receiving direct 
entorhinal input, presumably on dendrites containing dysbindin-1 
that we found to extend far into the dentate molecular layer.
DGh cells regulate HF information flow because (a) they have 
a lower firing threshold for entorhinal input than DGg cells (66, 
67), (b) they receive input from DGg cells (49), and (c) they give 
rise to a recurrent, glutamatergic projection that ends on proxi-
mal dendrites of DGg cells over long rostrocaudal segments of the 
DG (62–64). Via that recurrent projection, DGh cells can prime 
or recruit large numbers of granule cells to respond to entorhinal 
input. Moreover, they do so in a manner found to support long-
term potentiation in the granule cells (62). As explained above, the 
recurrent DGh output just described (Figure 10C) terminates in the 
conspicuous band of dysbindin-1 and VGluT-1 immunoreactivity 
we observed in DGiml. The dysbindin-1 reduction observed there 
in schizophrenia cases may thus alter normal information process-
ing and diminish synaptic plasticity in the DG.
Information flow downstream from the DG may also be dis-
rupted by the dysbindin-1 reductions observed in CA3 strata oriens 
and radiatum of schizophrenia cases. Via mossy fiber projections, 
DGg cells innervate not only dysbindin-1–positive DGh cells, but 
also dendrites of dysbindin-1–positive CA3 pyramidal neurons. 
Those neurons are glutamatergic (68) with many axon collaterals 
(69), some of which (i.e., Schaffer collaterals) send output further 
downstream to CA1 and thereby return information back to the 
entorhinal cortex (48, 49). Other collaterals (Figure 10C) are recur-
rent and innervate cell-poor layers containing dendrites of CA3 
pyramidal neurons, including strata oriens and radiatum (69). Such 
collaterals provide an excitatory-feedback pathway, impairment of 
which may contribute to the associative memory deficits observed 
in mice lacking N-methyl-D-aspartate (NMDA) receptors specifically 
in CA3 (70). As in DGh projections, then, reduction of dysbindin-1 
in recurrent CA3 collaterals may alter information processing and 
diminish synaptic plasticity. The same may be true for CA3 Schaffer 
collaterals to CA1, excitation of which can normally induce long-
term potentiation in CA1 via glutamatergic mechanism (71).
There are thus at least three sites in the HF where presynaptic 
dysbindin-1 reductions found in schizophrenia may disrupt 
cognitive processes. The effect would be widespread in the HF, 
because projections of individual DGh and CA3 pyramidal neu-
rons innervate extensive rostrocaudal segments of the HF (49, 67). 
Those lengthy association projections are important in forming 
associations between different sensory modalities, which innervate 
largely separate rostrocaudal segments of the HF (72). It has been 
proposed, moreover, that CA3 and DG collectively play an impor-
tant role in episodic memory, specifically in storage and retrieval 
of memory sequences in context (73). HF dysbindin-1 losses in 
schizophrenia may thus contribute to cognitive deficits common 
in that disorder (74), including those in episodic memory (75).
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